Dupilumab,
does it really help with Clinically meaningful itch reduction and nodule improvement in uncontrolled prurigo nodularis?
research showsThe grade is C. In the all-randomized analyses of PRIME, 151 participants, and PRIME2, 160 participants, a four-point itch response occurred in 60.0% versus 18.4% and 37.2% versus 22.0%; both primary endpoints succeeded. At week 24, 48.0% versus 18.4% and 44.9% versus 15.9% had five or fewer nodules. The effects were large, but both trials belonged to one Sanofi-Regeneron program, giving C with 54 points.
ads claimClaims should report both the 12- and 24-week response windows. Two trials within one sponsor program should not be described as two independent confirmations.
Useful facts when choosing a product
- Dupilumab is a subcutaneous monoclonal antibody blocking IL-4R alpha, shared by IL-4 and IL-13 signaling.
- PRIME and PRIME2 followed adults with at least 20 nodules inadequately controlled by prescription topical therapy for 24 weeks.
- Existing dupilumab verdicts concern atopic dermatitis, COPD, chronic rhinosinusitis with polyps, and eosinophilic esophagitis, not this indication.
Chamgap Semantic Classification Code
Candidate index · review held
M.dupilumab.UNK.clinically-meaningful-itch-reduction-and-nodule-improvement-in-uncontrolled-prurigo-nodularis.reduce.placeboMedicinal interventions > Dupilumab > Unknown > Clinically meaningful itch reduction and nodule improvement in uncontrolled prurigo nodularis > Reduction claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
PRIME randomized 151 participants and PRIME2 randomized 160, with all participants included in their analyses. The primary endpoint was a four-point WI-NRS response at week 24 in PRIME and week 12 in PRIME2; both succeeded. The key week-24 endpoint of five or fewer nodules was 48.0% versus 18.4% and 44.9% versus 15.9%, both P<0.001. Authors overlapped, Sanofi and Regeneron developed both protocols, and the sponsors analyzed the data.
Why this is classified as C (54)
Both itch primary endpoints and nodule key secondary endpoints succeeded with clinically meaningful effects, but evidence was confined to one Sanofi-Regeneron development program, giving C with 54 points.
Counterpoint. Nemolizumab addresses the same disease but is a different drug; verdict 1877 is C with 54 points. Both verdicts use the same manufacturer-only-program independence ceiling.
Rejudgment record. Cross-check applied — Both manufacturer phase 3 trials succeeded on itch primary and nodule key secondary endpoints, but they shared sponsors, authors, and one development program
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Clinically meaningful itch reduction | C | Four-point responses were 60.0% versus 18.4% and 37.2% versus 22.0%. |
| Week-24 nodule improvement | C | Five or fewer nodules occurred in 48.0% versus 18.4% and 44.9% versus 15.9%. |
| Concurrent improvement in itch and nodules | C | Both itch primary endpoints and week-24 nodule key secondary endpoints succeeded in both trials. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Yosipovitch et al. 2023 PRIME | Multicenter randomized double-blind placebo-controlled phase 3 trial | 151 randomized and analyzed | Sponsored by Sanofi and Regeneron; sponsors developed the protocol and analyzed data | Primary week-24 four-point WI-NRS responder proportion; key secondary five or fewer nodules at week 24 | Itch responders 60.0% versus 18.4%, adjusted difference 42.7 points (95% CI 27.8 to 57.7), P<0.001; nodules 48.0% versus 18.4%, P<0.001. | Pivotal manufacturer confirmatory trial |
| Yosipovitch et al. 2023 PRIME2 | Multicenter randomized double-blind placebo-controlled phase 3 trial in the same development program | 160 randomized and analyzed | Sponsored by Sanofi and Regeneron; same program as PRIME | Primary week-12 four-point WI-NRS responder proportion; key secondary five or fewer nodules at week 24 | Itch responders 37.2% versus 22.0%, adjusted difference 16.8 points (95% CI 2.3 to 31.2), P=0.022; nodules 44.9% versus 15.9%, P<0.001. | Replication within the same manufacturer program |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-01).
Final verification and publication gate: Codex · Evidence date: 2026-08-01 · Corrections: none
Cite this verdict
[Chamgap] Dupilumab x itch and nodule improvement in prurigo nodularis — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/dupilumab-prurigo-nodularis-itch-nodule-improvement/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.